While the individual impact of an infection can range from fairly mild to a major health concern, COVID-19 was a reminder that a virus’ ability to spread and mutate rapidly can create disruption on a broad scale. Scientists are creating vaccines that inhibit viral proteins without damaging host cells.
HRHR has been at the forefront of clinical trials for a variety of vaccines.
- Pneumococcal conjugate vaccine approved June 2022
- COVID-19 vaccine approved June 2022